Autologous non-bulbar dermal sheath fibroblast therapy - RepliCel Life Sciences

Drug Profile

Autologous non-bulbar dermal sheath fibroblast therapy - RepliCel Life Sciences

Alternative Names: NBDS fibroblast therapy - RepliCel; RCS-01; RCT-01; RCT-A-01; RCT-P-01; RepliCel Tendon-01; Skin aging therapy - RepliCel; Skin rejuvenation - RepliCel; Tendon repair - RepliCel

Latest Information Update: 03 May 2017

Price : $50

At a glance

  • Originator RepliCel Life Sciences; Royal National Orthopaedic Hospital; Royal University Hospital
  • Class Fibroblast cell therapies
  • Mechanism of Action Cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Tendon injuries
  • Phase I Skin aging

Most Recent Events

  • 25 Apr 2017 RepliCel Life Sciences has patent protection for RCI 02 in USA
  • 04 Apr 2017 Interim adverse events and pharmacodynamics data from a phase I study in Healthy volunteers released by RepliCel Life Sciences
  • 28 Mar 2017 Interim efficacy and adverse events data from the phase I/II ReaCT trial in Achilles tendinosis released by RepliCel Life Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top